Delivery Order SPE2DR25D3012-SPE2DR26F4D2L
- Not listed
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a $1,941.36 delivery order to AmerisourceBergen Drug Corp for INBRIJA 42 mg Inhalation Capsules (60-count) on August 25, 2025, with completion scheduled for September 16, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion and extending through December 2026. The award was competitively...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,132.50 to AmerisourceBergen Drug Corp for INBRIJA 42 mg inhalation capsules (60-count) on December 18, 2025, with an ultimate completion date of January 12, 2026. This firm fixed-price delivery order, which carries no set-aside designation, will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal healthcare vendor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 2, 2025, for the supply of INBRIJA 42 mg inhalation capsules (60-count units) with a ceiling value of $1,941.36. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures and scheduled for completion by May 23, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- This delivery order, valued at $3,882.72, awards AmerisourceBergen Drug Corp the supply of INBRIJA 42 MG inhalation capsules (60-count units) under a firm fixed price contract with the Defense Logistics Agency's Medical Supply Chain. The award was made on September 16, 2025, without a set-aside designation, indicating the contract was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $1,941.36 for INBRIJA 42 mg inhalation capsules (60-count) by the Defense Logistics Agency's Medical Supply Chain, a division of the Department of Defense. The contract, awarded on May 30, 2025, with an ultimate completion date of June 23, 2025, represents a firm fixed-price, competitively awarded procurement with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of INBRIJA 42 MG INHALATION CAP 60S. The contract has a completion date of February 22, 2024 and a potential value of $1,876.50. As the prime contractor, Amerisourcebergen Drug Corp will provide these pharmaceutical products from its corporate office located in Conshohocken, Pennsylvania. The...
- The U.S. Defense Logistics Agency (DLA) awarded a $1,251.00 Firm Fixed Price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4564542915 INBRIJA 42 MG INHALATION CAP 60S. The contract has an ultimate completion date of May 30, 2024. This order is placed under AmerisourceBergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. The IDC allows the DLA to...
- This is a $1,294.24 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of INBRIJA 42 MG INHALATION CAP 60S. The contract has an ultimate completion date of July 21, 2025 and is not set aside. AmerisourceBergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support...
- Amerisourcebergen Drug Corp has been awarded a firm fixed price delivery order against its indefinite delivery contract with the Defense Logistics Agency (DLA) Troop Support Medical. Valued at $1,251, this order is for the supply of 60 units of INBRIJA 42 MG inhalation capsules to support DLA medical facilities. Performance will take place at Amerisourcebergen's headquarters in Conshohocken, Pennsylvania, with completion by December 18, 2023. No set aside designation was applied to this award to...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has received a $1,876.50 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to supply 60 units of the 42 mg Inbrija inhalation cap medication. Performance will take place at Amerisourcebergen's headquarters in Conshohocken, Pennsylvania, with all supplies delivered by December 11, 2023. No set-aside designation was applied to this award made under the prime vendor's existing...
- SPE2DR25D3012Indefinite Delivery Contract
- SPE2DR25D3012-SPE2DR26F4D2LDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of Inbrija 42 mg inhalation capsules (60-count package) under a firm fixed-price contract with a ceiling value of $1,879.50. This competitive award, with no set-aside designation, utilizes the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle valued through December 2026. Performance of this order is scheduled for completion by January 2, 2026, at AmerisourceBergen's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. The company's extensive federal contract portfolio demonstrates its capability to supply a broad range of pharmaceutical products, including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. This delivery order represents a routine pharmaceutical supply transaction within the company's broader framework of supporting defense healthcare requirements globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 12/9/25 |